Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2017

21.10.2016 | Translational Research and Biomarkers

FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer

verfasst von: Haruyoshi Tanaka, MD, Mitsuro Kanda, MD, PhD, FACS, Dai Shimizu, MD, PhD, Chie Tanaka, MD, PhD, Daisuke Kobayashi, MD, PhD, Masamichi Hayashi, MD, PhD, Naoki Iwata, MD, PhD, Suguru Yamada, MD, PhD, FACS, Tsutomu Fujii, MD, PhD, FACS, Goro Nakayama, MD, PhD, Hiroyuki Sugimoto, MD, PhD, Michitaka Fujiwara, MD, PhD, Yukiko Niwa, MD, PhD, Yasuhiro Kodera, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

ABSTRACT

Background

Gastric cancer (GC) relapse can occur even if curative resection is achieved. Biomarkers predicting recurrence are needed to provide appropriate postoperative surveillance and perioperative therapeutic strategy.

Methods

A global expression profiling was performed using tissues from GC patients with synchronous liver-confined metastasis. Family with sequence similarity 46, member C (FAM46C), was identified as a candidate biomarker. mRNA expression analysis, direct nucleotide sequencing, bisulfite sequencing and copy number assays for FAM46C were performed with eleven GC cell lines. Expression levels of FAM46C in primary GC tissues from 129 patients who underwent curative GC resection were determined and correlated with clinicopathological factors, including postoperative outcome.

Results

Levels of FAM46C mRNA differed among GC cell lines. Point mutations in FAM46C were detected in five GC cell lines accompanied with reduced FAM46C transcription. No hypermethylation was found in the promoter region of FAM46C. Copy number alterations were found in six GC cell lines with differing FAM46C transcription levels. Reduced FAM46C mRNA expression levels were detected in 117 (91 %) GC specimens compared with adjacent noncancerous tissues. Low FAM46C expression levels were significantly associated with larger macroscopic GC tumor sizes. The low FAM46C expression group was likely to have shorter disease-free survival than the high group and low FAM46C level was identified as an independent risk factor for recurrence after curative resection. FAM46C expression levels were low in all cases that were later found to have hepatic recurrence.

Conclusions

Reduced GC expression of FAM46C is a potential biomarker to predict hepatic recurrence after curative gastrectomy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015;158:1573–80.CrossRefPubMed Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015;158:1573–80.CrossRefPubMed
4.
Zurück zum Zitat Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics. 2012;75:3081–97.CrossRefPubMed Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics. 2012;75:3081–97.CrossRefPubMed
5.
Zurück zum Zitat Kanda M, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138:721–30.CrossRefPubMed Kanda M, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138:721–30.CrossRefPubMed
6.
7.
Zurück zum Zitat Brosnan JA, Iacobuzio-Donahue CA. A new branch on the tree: next-generation sequencing in the study of cancer evolution. Semin Cell Dev Biol. 2012;23:237–42.CrossRefPubMedPubMedCentral Brosnan JA, Iacobuzio-Donahue CA. A new branch on the tree: next-generation sequencing in the study of cancer evolution. Semin Cell Dev Biol. 2012;23:237–42.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS ONE. 2015;10:e0126670.CrossRefPubMedPubMedCentral Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS ONE. 2015;10:e0126670.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Kanda M, Shimizu D, Tanaka H, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667–79.CrossRefPubMedPubMedCentral Kanda M, Shimizu D, Tanaka H, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667–79.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kanda M, Tanaka C, Kobayashi D, et al. Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Int J Cancer. 2016;139:2290–8.CrossRefPubMed Kanda M, Tanaka C, Kobayashi D, et al. Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Int J Cancer. 2016;139:2290–8.CrossRefPubMed
11.
Zurück zum Zitat Sobin LH, Gospodarowicz MK. TNM classification of malignant tumors. 7th edn. New York: Wiley-Blackwell: 2009 Sobin LH, Gospodarowicz MK. TNM classification of malignant tumors. 7th edn. New York: Wiley-Blackwell: 2009
12.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edn. Gastric cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edn. Gastric cancer. 2011;14:101–12.CrossRef
13.
Zurück zum Zitat Tanaka H, Kanda M, Koike M, et al. Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. Int J Oncol. 2015;47:1811–8.CrossRefPubMed Tanaka H, Kanda M, Koike M, et al. Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. Int J Oncol. 2015;47:1811–8.CrossRefPubMed
14.
Zurück zum Zitat Oya H, Kanda M, Sugimoto H, et al. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590–600.CrossRefPubMed Oya H, Kanda M, Sugimoto H, et al. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590–600.CrossRefPubMed
15.
Zurück zum Zitat Ezaka K, Kanda M, Sugimoto H, et al. Reduced expression of adherens junctions associated protein 1 predicts recurrence of hepatocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 2015;22 Suppl 3:1499–507.CrossRef Ezaka K, Kanda M, Sugimoto H, et al. Reduced expression of adherens junctions associated protein 1 predicts recurrence of hepatocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 2015;22 Suppl 3:1499–507.CrossRef
16.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
17.
Zurück zum Zitat Boyd KD, Ross FM, Walker BA, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17:7776–84.CrossRefPubMed Boyd KD, Ross FM, Walker BA, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17:7776–84.CrossRefPubMed
18.
Zurück zum Zitat Barbieri M, Manzoni M, Fabris S, et al. Compendium of FAM46C gene mutations in plasma cell dyscrasias. Br J Haematol. 2015;174:642–5.CrossRefPubMed Barbieri M, Manzoni M, Fabris S, et al. Compendium of FAM46C gene mutations in plasma cell dyscrasias. Br J Haematol. 2015;174:642–5.CrossRefPubMed
19.
Zurück zum Zitat Affer M, Chesi M, Chen WD, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28:1725–35.CrossRefPubMedPubMedCentral Affer M, Chesi M, Chen WD, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28:1725–35.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Chesi M, Bergsagel PL. Advances in the pathogenesis and diagnosis of multiple myeloma. Int J Lab Hematol. 2015;37 Suppl 1:108–14.CrossRefPubMed Chesi M, Bergsagel PL. Advances in the pathogenesis and diagnosis of multiple myeloma. Int J Lab Hematol. 2015;37 Suppl 1:108–14.CrossRefPubMed
21.
Zurück zum Zitat Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481–5.CrossRefPubMedPubMedCentral Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481–5.CrossRefPubMedPubMedCentral
22.
23.
Zurück zum Zitat Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed
25.
Zurück zum Zitat Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.CrossRefPubMed Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.CrossRefPubMed
26.
Zurück zum Zitat Kanda M, Kobayashi D, Tanaka C, et al. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer. 2016;19:255–63.CrossRefPubMed Kanda M, Kobayashi D, Tanaka C, et al. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer. 2016;19:255–63.CrossRefPubMed
27.
Zurück zum Zitat Kanda M, Mizuno A, Fujii T, et al. Tumor infiltrative pattern predicts sites of recurrence after curative gastrectomy for stages 2 and 3 gastric cancer. Ann Surg Oncol. 2016;23:1934–40.CrossRefPubMed Kanda M, Mizuno A, Fujii T, et al. Tumor infiltrative pattern predicts sites of recurrence after curative gastrectomy for stages 2 and 3 gastric cancer. Ann Surg Oncol. 2016;23:1934–40.CrossRefPubMed
28.
Zurück zum Zitat Kodera Y, Fujitani K, Fukushima N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17:206–12.CrossRefPubMed Kodera Y, Fujitani K, Fukushima N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17:206–12.CrossRefPubMed
29.
Zurück zum Zitat Oki E, Tokunaga S, Emi Y, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968–76.CrossRefPubMed Oki E, Tokunaga S, Emi Y, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968–76.CrossRefPubMed
Metadaten
Titel
FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer
verfasst von
Haruyoshi Tanaka, MD
Mitsuro Kanda, MD, PhD, FACS
Dai Shimizu, MD, PhD
Chie Tanaka, MD, PhD
Daisuke Kobayashi, MD, PhD
Masamichi Hayashi, MD, PhD
Naoki Iwata, MD, PhD
Suguru Yamada, MD, PhD, FACS
Tsutomu Fujii, MD, PhD, FACS
Goro Nakayama, MD, PhD
Hiroyuki Sugimoto, MD, PhD
Michitaka Fujiwara, MD, PhD
Yukiko Niwa, MD, PhD
Yasuhiro Kodera, MD, PhD, FACS
Publikationsdatum
21.10.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5636-y

Weitere Artikel der Ausgabe 11/2017

Annals of Surgical Oncology 11/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.